Disc Medicine, Inc. presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0974 at the ASH Annual Meeting, showing substantial reductions in hepcidin and increases in iron levels for patients with anemia of MF. Anemia response was observed across all patient subgroups, regardless of baseline transfusion status, and was independent of concomitant JAK inhibitor therapy use. The trial enrolled 47 adult patients, with consistent, substantial decreases in hepcidin and corresponding increases in serum iron levels. DISC-0974 dosing was associated with improvements in fatigue scores and was generally well-tolerated, with only minor adverse events reported. Additional data will be shared in the second half of 2026.

In addition to the RALLY-MF Phase 2 trial, Disc Medicine also shared a poster overviewing the ongoing Phase 2 study of the anti-TMPRSS6 antibody DISC-3405 in polycythemia vera requiring frequent phlebotomy. Management will host a call during the ASH meeting to review highlights of the presented data and discuss plans for next steps in development on Sunday, December 7, at 7:30 am EST. Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for patients with serious hematologic diseases. They are dedicated to addressing unmet needs in treating anemia and other hematologic conditions by targeting fundamental biological pathways.

Read more at GlobeNewswire: Disc Medicine Presents Positive Initial Data from RALLY-MF